Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of IMR-687 in adults with sickle cell anaemia
2017-000653-39Phase 2Unknown
- Sponsor
- Imara, Inc
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tovinontrine in sickle cell anemia (SCA) and sickle cell disease (SCD) (4 arms), sponsored by Imara, Inc. Primary endpoint: Safety and tolerability of IMR-687. Status: unknown.
02
Drugs
tovinontrine
03
Conditions
sickle cell anemia (SCA)sickle cell disease (SCD)
Beyond the preview
Go deeper on 2017-000653-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000653-39.